<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309360</url>
  </required_header>
  <id_info>
    <org_study_id>A 2009 24</org_study_id>
    <nct_id>NCT01309360</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Axillary Plexus Block - Dose Reduction of Prilocaine</brief_title>
  <official_title>Ultrasound-guided Block of the Brachial Plexus Using Prilocaine: Effects of Local-anesthetic Dose Reduction on Parameters of Block Quality and Adverse Effects in Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helios Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helios Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical aim: Does reducing the dose of local anesthetic in ultrasound-guided axillary plexus
      anesthesia have any effect on the success rate and additional parameters of block quality?
      Methodology: In this prospective cohort study three groups of 40 outpatients each were
      administered dosages of 1% prilocaine of either 40mL, 30mL or 20mL for axillary plexus
      anesthesia. Met-Hb was measured prior to administration of the block and then hourly until
      the Met-Hb concentration fell. Parameters of block quality and any adverse effects were
      recorded. The level of significance was defined with α ≤ 0.05.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      With the availability of high resolution portable ultrasound equipment, the use of sonography
      in the field of anesthesia has become more widespread in recent years. The investigators
      would like to draw attention to a meta-analysis of prospective randomized studies by Abrahams
      et al. as being representative of the numerous publications available. Compared to nerve
      stimulation, ultrasound-guided nerve blocks have a higher success rate with significantly
      fewer vascular punctures and shorter procedure times. However, the administration of
      ultrasound-guided regional anesthesia necessitates considerable equipment acquisition and
      training expenses. Nevertheless, the suggested benefits resulting from savings in time and
      local anesthetic, increased patient satisfaction and avoidance of complications should be
      considered in addition to the results from Abrahams et al.

      The aim of the present work was to investigate whether an ultrasound-guided block combined
      with a reduced dose of the local anesthetic prilocaine altered the success rate or other
      parameters of block quality. Any adverse effects and the methaemoglobin concentration were
      also recorded.

      Methodology

      After receiving ethics committee approval and after informing patients, ultrasound-guided
      axillary plexus anesthesia was carried out on 120 adult outpatients in ASA risk groups I-II.
      The surgical spectrum covered procedures on the distal forearm or the hand (carpal tunnel
      syndrome, ganglion extirpation, removal of material, etc.). Provision of information and
      inclusion in the study was done in the anesthesia outpatients' clinic as part of the standard
      preoperative preparation. Prior to administering the regional anesthesia the investigators
      administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
      Application of the local anesthesia was done prospectively and single blind in 3 cohorts with
      decreasing dosage. The patients received either 400mg (group A), 300mg (group B) or 200mg
      (group C) of prilocaine 1%. The block was performed under sterile conditions using a portable
      ultrasound device (Sonosite S-Nerve) and a 24 G short bevel cannula with flexible tubing. The
      block was performed using combined out-of-plane (n. musculocutaneous) and in-plane techniques
      (n.radialis, n.medianus, n.ulnaris), usually from a single puncture site. The outpatients
      were cared for in the anesthesia care unit preoperatively and postoperatively until their
      discharge. NIBP, pulse oxymetry and ECG were continuously monitored. The discharge criteria
      were widespread regression of the block with a subjective feeling of well-being including
      adequate analgesia and stable vital signs with methemoglobin (Met-Hb) concentrations ≤ 5%.
      Met-Hb levels were measured using spectrophotometry prior to the anesthesia (baseline value)
      and then hourly after performing the block until a clear decrease became apparent. A complete
      sensory block of all 4 nerves within 60 minutes of administration of the local anesthetic was
      rated as a successful block.

      For the statistical analysis the investigators selected distribution-free, nonparametric test
      methods. The Mann-Whitney U test was used when comparing 2 groups and the Kruskal-Wallis test
      or Fisher's exact test was used when comparing more than 2 groups. The level of significance
      was defined with α ≤ 0.05. With multiple paired comparisons the significance level was
      adjusted using the Bonferroni correction. The Bravais-Pearson correlation coefficient rho
      describes the relationship between the maximum Met-Hb value and the weight-based prilocaine
      dose in mg/kg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Sensory Block</measure>
    <time_frame>60 minutes after administration of the local anesthetic</time_frame>
    <description>The number of outpatients with complete sensory block of all 4 nerves (n.musculocutaneous, n.radialis, n.ulnaris,n.medianus) was registrated in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Complete Motor Blocks</measure>
    <time_frame>Within 60 minutes after administration of the local anesthetic</time_frame>
    <description>To examine the extent of the motor block the manual muscle function test after Vladimir Janda was used. As a complete motor block was defined, when no motion (grade zero after Janda) of muscles innervated by the four blocked nerves (musculocutaneous, median, radial and ulnar nerve) was observed within 60 minutes after administration of the local anesthetic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset Time.</measure>
    <time_frame>within 60 minutes after administration of the local anesthetic</time_frame>
    <description>Time from beginning of administration of the local anesthetic until complete sensoric block.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentrations of Methemoglobin</measure>
    <time_frame>0,1,2,3,4 hours post-dose</time_frame>
    <description>Concentration of Methemoglobin (Met-Hb) was measured using spectrophotometry prior to the anesthesia (baseline value) and then hourly after performing the block until a clear decrease became apparent. The maximum amount was reached in every case two or three hours after administration of the local anesthetic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Objective Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Outpatients were followed for the duration of hospital stay, an average of six hours.</time_frame>
    <description>In groups A, B and C was determined the rate of objective clinical signs of increased Met-Hb-levels : drops in oxygen saturation &lt;93% using pulseoximetry or lip cyanosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Subjective Adverse Events as a Measure of Safety and Tolerability.</measure>
    <time_frame>Outpatients were followed for the duration of hospital stay, an average of six hours.</time_frame>
    <description>In groups A, B and C was determined the rate of subjective clinical signs of increased Met-Hb-Levels : headaches or dizziness, when correlated with the peak-Met-Hb-Level.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Other Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>group A : 40ml Prilocaine 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B : 30ml Prilocaine 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C : 20ml Prilocaine 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).</description>
    <arm_group_label>group A : 40ml Prilocaine 1%</arm_group_label>
    <arm_group_label>group B : 30ml Prilocaine 1%</arm_group_label>
    <arm_group_label>group C : 20ml Prilocaine 1%</arm_group_label>
    <other_name>Dormicum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prilocaine 1%</intervention_name>
    <description>40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block</description>
    <arm_group_label>group A : 40ml Prilocaine 1%</arm_group_label>
    <other_name>Xylonest 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prilocaine 1%</intervention_name>
    <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
    <arm_group_label>group B : 30ml Prilocaine 1%</arm_group_label>
    <other_name>Xylonest 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prilocaine 1%</intervention_name>
    <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
    <arm_group_label>group C : 20ml Prilocaine 1%</arm_group_label>
    <other_name>Xylonest 1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective surgery on the distal forearm or the hand

          -  adult outpatients, age 18-75 years old

          -  ASA-risk groups I-II (American Society of Anesthesiologists)

          -  Body Mass Index 17-35

          -  informed consent

        Exclusion Criteria:

          -  severe coagulopathy

          -  local or systemic inflammatory response

          -  ASA-risk groups ≥ Grad III

          -  severe anemia

          -  heart failure

          -  manifest shock

          -  other drugs with influence on methaemoglobinemia (nitrates, sulfonamides etc.)

          -  domestic care after surgery not ensured

          -  drug allergy : local anesthetics

          -  severe polyneuropathy

          -  pregnancy, lactation period

          -  participation in other studies

          -  non-cooperative patients

          -  addiction to drugs or alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Seidel, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anästhesiologie und Intensivtherapie, Helios Kliniken Schwerin, Wismarsche Strasse 393-7, DE-19049 Schwerin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg Rehmert, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>Klinik für Anästhesiologie und Intensivtherapie, Helios Kliniken Schwerin, Wismarsche Strasse 393-7, DE-19049 Schwerin</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <results_first_submitted>May 4, 2011</results_first_submitted>
  <results_first_submitted_qc>May 31, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2011</results_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr.med. Ronald Seidel</name_title>
    <organization>Klinik für Anästhesiologie und Intensivtherapie, Helios Kliniken Schwerin, Wismarsche Strasse 393-7, DE-19049 Schwerin</organization>
  </responsible_party>
  <keyword>ultrasound</keyword>
  <keyword>methaemoglobin</keyword>
  <keyword>prilocaine</keyword>
  <keyword>regional anesthesia</keyword>
  <keyword>ASA risk groups I-II</keyword>
  <keyword>adult outpatients</keyword>
  <keyword>surgical spectrum covered procedures</keyword>
  <keyword>distal forearm</keyword>
  <keyword>hand</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Provision of information and inclusion in the study was done in the anesthesia outpatients clinic as part of the standard preoperative preparation.</recruitment_details>
      <pre_assignment_details>Outpatients were prematurely dropped out for medical or non-medical reasons. Non-medical reasons:1.recall of the approval by the patient, 2.unavailability of the ultrasound-machine, 3.the planned operation was not carried out. Medical reasons: severe complications like systemic toxicity of the local anesthetic (seizure, cardiac arrest).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A : 40ml Prilocaine 1%</title>
          <description>40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block</description>
        </group>
        <group group_id="P2">
          <title>Group B : 30ml Prilocaine 1%</title>
          <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
        </group>
        <group group_id="P3">
          <title>Group C : 20ml Prilocaine 1%</title>
          <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A : 40ml Prilocaine 1%</title>
          <description>40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block</description>
        </group>
        <group group_id="B2">
          <title>Group B : 30ml Prilocaine 1%</title>
          <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
        </group>
        <group group_id="B3">
          <title>Group C : 20ml Prilocaine 1%</title>
          <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="14"/>
                    <measurement group_id="B2" value="47" spread="16"/>
                    <measurement group_id="B3" value="45" spread="16"/>
                    <measurement group_id="B4" value="47" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>percentage of methemoglobin</title>
          <description>Baseline levels of Met-Hb (percentage of methemoglobin) were measured using spectrophotometry prior to the anesthesia.</description>
          <units>percentage of methemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.84" spread="0.15"/>
                    <measurement group_id="B2" value="0.9" spread="0.16"/>
                    <measurement group_id="B3" value="0.86" spread="0.17"/>
                    <measurement group_id="B4" value="0.87" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Sensory Block</title>
        <description>The number of outpatients with complete sensory block of all 4 nerves (n.musculocutaneous, n.radialis, n.ulnaris,n.medianus) was registrated in each group.</description>
        <time_frame>60 minutes after administration of the local anesthetic</time_frame>
        <population>The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A : 40ml Prilocaine 1%</title>
            <description>40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O2">
            <title>Group B : 30ml Prilocaine 1%</title>
            <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O3">
            <title>Group C : 20ml Prilocaine 1%</title>
            <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Sensory Block</title>
          <description>The number of outpatients with complete sensory block of all 4 nerves (n.musculocutaneous, n.radialis, n.ulnaris,n.medianus) was registrated in each group.</description>
          <population>The analysis was per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentrations of Methemoglobin</title>
        <description>Concentration of Methemoglobin (Met-Hb) was measured using spectrophotometry prior to the anesthesia (baseline value) and then hourly after performing the block until a clear decrease became apparent. The maximum amount was reached in every case two or three hours after administration of the local anesthetic.</description>
        <time_frame>0,1,2,3,4 hours post-dose</time_frame>
        <population>Methemoglobin (Met-Hb) levels were measured using spectrophotometry prior to the anesthesia (baseline value) and then hourly after performing the block until a clear decrease became apparent.The mean maximum Met-Hb was estimated in each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A : 40ml Prilocaine 1%</title>
            <description>40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O2">
            <title>Group B : 30ml Prilocaine 1%</title>
            <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O3">
            <title>Group C : 20ml Prilocaine 1%</title>
            <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentrations of Methemoglobin</title>
          <description>Concentration of Methemoglobin (Met-Hb) was measured using spectrophotometry prior to the anesthesia (baseline value) and then hourly after performing the block until a clear decrease became apparent. The maximum amount was reached in every case two or three hours after administration of the local anesthetic.</description>
          <population>Methemoglobin (Met-Hb) levels were measured using spectrophotometry prior to the anesthesia (baseline value) and then hourly after performing the block until a clear decrease became apparent.The mean maximum Met-Hb was estimated in each group.</population>
          <units>percentage of methemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.1"/>
                    <measurement group_id="O2" value="3.7" spread="1.3"/>
                    <measurement group_id="O3" value="2.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Objective Adverse Events as a Measure of Safety and Tolerability</title>
        <description>In groups A, B and C was determined the rate of objective clinical signs of increased Met-Hb-levels : drops in oxygen saturation &lt;93% using pulseoximetry or lip cyanosis.</description>
        <time_frame>Outpatients were followed for the duration of hospital stay, an average of six hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A : 40ml Prilocaine 1%</title>
            <description>40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O2">
            <title>Group B : 30ml Prilocaine 1%</title>
            <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O3">
            <title>Group C : 20ml Prilocaine 1%</title>
            <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Adverse Events as a Measure of Safety and Tolerability</title>
          <description>In groups A, B and C was determined the rate of objective clinical signs of increased Met-Hb-levels : drops in oxygen saturation &lt;93% using pulseoximetry or lip cyanosis.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Motor Blocks</title>
        <description>To examine the extent of the motor block the manual muscle function test after Vladimir Janda was used. As a complete motor block was defined, when no motion (grade zero after Janda) of muscles innervated by the four blocked nerves (musculocutaneous, median, radial and ulnar nerve) was observed within 60 minutes after administration of the local anesthetic.</description>
        <time_frame>Within 60 minutes after administration of the local anesthetic</time_frame>
        <population>The analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A : 40ml Prilocaine 1%</title>
            <description>40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O2">
            <title>Group B : 30ml Prilocaine 1%</title>
            <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O3">
            <title>Group C : 20ml Prilocaine 1%</title>
            <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Motor Blocks</title>
          <description>To examine the extent of the motor block the manual muscle function test after Vladimir Janda was used. As a complete motor block was defined, when no motion (grade zero after Janda) of muscles innervated by the four blocked nerves (musculocutaneous, median, radial and ulnar nerve) was observed within 60 minutes after administration of the local anesthetic.</description>
          <population>The analysis was per protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Onset Time.</title>
        <description>Time from beginning of administration of the local anesthetic until complete sensoric block.</description>
        <time_frame>within 60 minutes after administration of the local anesthetic</time_frame>
        <population>In some cases the investigators were not able to exactly determine an onset time, so in cases of block failure (supplementation needed) or emergency situations outside this study (onset time not examined). Therefore the number of participants analyzed concerning onset time is lower then the total number of outpatients in each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A : 40ml Prilocaine 1%</title>
            <description>40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O2">
            <title>Group B : 30ml Prilocaine 1%</title>
            <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O3">
            <title>Group C : 20ml Prilocaine 1%</title>
            <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
        </group_list>
        <measure>
          <title>Onset Time.</title>
          <description>Time from beginning of administration of the local anesthetic until complete sensoric block.</description>
          <population>In some cases the investigators were not able to exactly determine an onset time, so in cases of block failure (supplementation needed) or emergency situations outside this study (onset time not examined). Therefore the number of participants analyzed concerning onset time is lower then the total number of outpatients in each group.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="7"/>
                    <measurement group_id="O2" value="20" spread="8"/>
                    <measurement group_id="O3" value="26" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.247</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Subjective Adverse Events as a Measure of Safety and Tolerability.</title>
        <description>In groups A, B and C was determined the rate of subjective clinical signs of increased Met-Hb-Levels : headaches or dizziness, when correlated with the peak-Met-Hb-Level.</description>
        <time_frame>Outpatients were followed for the duration of hospital stay, an average of six hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A : 40ml Prilocaine 1%</title>
            <description>40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O2">
            <title>Group B : 30ml Prilocaine 1%</title>
            <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
          <group group_id="O3">
            <title>Group C : 20ml Prilocaine 1%</title>
            <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Subjective Adverse Events as a Measure of Safety and Tolerability.</title>
          <description>In groups A, B and C was determined the rate of subjective clinical signs of increased Met-Hb-Levels : headaches or dizziness, when correlated with the peak-Met-Hb-Level.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.116</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.116</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A : 40ml Prilocaine 1%</title>
          <description>40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block</description>
        </group>
        <group group_id="E2">
          <title>Group B : 30ml Prilocaine 1%</title>
          <description>40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block</description>
        </group>
        <group group_id="E3">
          <title>Group C : 20ml Prilocaine 1%</title>
          <description>40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>objective signs of methemoglobinemia</sub_title>
                <description>As objective signs of increased concentration of methemoglobin we registrated lip cyanosis and/or drops in oxygen concentration measured with an standard two-wavelength-pulseoximeter.</description>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <description>Related to regional anesthesia when occuring during the peak of Met-Hb-formation.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>headaches</sub_title>
                <description>Related to regional anesthesia when occuring during the peak of Met-Hb-formation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.med.Ronald Seidel</name_or_title>
      <organization>Helios-Kliniken Schwerin</organization>
      <phone>0049 (0)385 520-4251</phone>
      <email>ronald.seidel@helios-kliniken.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

